Abstract:Abstract BACKGROUND As the global prevalence of inflammatory bowel disease (IBD) rises, it is important that the direst costs associated with medical care be analyzed to determine the impact on healthcare systems. Components making up the direct healthcare cost to the IBD population (e.g., hospitalizations, colonoscopies, and medications) are constantly changing and with this so may be the cost related to taking care of the IBD population. AIM Analyze component-specific costs, total costs, and the proportion of total costs attributed to each component, and changes over time. METHODS Using a validated algorithm and population-based administrative data from Alberta, Canada (Population: 4.3m), prevalent IBD patients were identified from fiscal year (FY) 2009/10 to 2018/19 (April 1–March 31). Costs from the Discharge Abstract Database, Physician Claims, National Ambulatory Care, and Pharmacy Information Network were converted to 2020 (CAD$) costs using Statistics Canada’s Consumer Price Index. Only IBD-related outpatient dispensed medications were included in the costs (inpatient not captured in data). Annual average costs per patient (with 95% confidence interval [CI]) were calculated. Medication costs per person were stratified on whether or not an individual was on a biologic (e.g. anti-TNF therapy) versus a non-biologic IBD-related medication (e.g., 5-ASA). The cost of an individual’s IBD-related hospitalization, IBD-related surgery, emergency department visit, colonoscopy, or IBD-related medication were calculated. Proportion of the total costs contributed by each category were calculated. Temporal trends of mean annual costs were analyzed using Poisson, or negative binomial, regression and average annual percentage change (AAPC) with 95%CI were reported. RESULTS In FY2018/19, the average cost of an IBD patient was $15,786 (95%CI:15,478, 16,094). This cost significantly increased from the 2009 value ($8,477; 95%CI: 8,407, 8,908) with an AAPC of 6.28% (95%CI: 5.51, 7.05). The annual costs of medications when a patient is on one or more biologics significantly increased (AAPC: 3.48%; 95%CI:2.32, 4.65). In contrast, the average annual cost per patient of IBD-related non-biologic medications significantly decreased (AAPC: -2.32; 95%CI: -3.48, -1.14). The largest contributor to IBD costs is medications (57.6% of the total costs) followed by IBD-related hospitalizations (20.6%). The costs of IBD-related hospitalizations and surgeries have remained stable, whereas the costs for emergency department visits and colonoscopies increased. DISCUSSION The costs associated with treating people IBD is rising and predominantly attributable to the cost of biologics. As the prevalence of IBD continues to increase, healthcare systems, payers and governments need to work to address these costs while ensuring these individuals receive the care they need. *Proportions will not add up to 100% as individuals can be captured in multiple cost categories each year (e.g., an IBD-related surgery cost is also captured as a hospitalization) and not all costs are reported in table. Overall and Biologics are Per Person; Hospitalization and Sugery are Per Event

Epidemiologic Burden and Treatment of Chronic Symptomatic Functional Bowel Disorders in the United States: A Nationwide Analysis

Prevalence and Risk Factors for Functional Bowel Disorders in South China: a Population Based Study Using the Rome III Criteria.

Economic Burden and Health Care Access for Patients with Inflammatory Bowel Diseases in China: Web-Based Survey Study

Tu2066 Prevalence of Irritable Bowel Syndrome in China: Joint Effects of Psychiatric Morbidity with Life Event Stress and Lactose Intake

Burden and Treatment of Chronic Upper GI Symptoms and Diagnoses – a Nationwide Study

Abdominal Pain and Depression, Not Bowel Habits, Predict Health Care Utilization in Patients With Functional Bowel Disorders

Chronic Constipation in the United States: Results From a Population-Based Survey Assessing Healthcare Seeking and Use of Pharmacotherapy

Burden of illness and treatment attitudes among participants meeting Rome IV criteria for irritable bowel syndrome: A nationwide survey in the United States

A Systematic Review of the Economic and Humanistic Burden of Illness in Irritable Bowel Syndrome and Chronic Constipation

COST-DRIVERS OF HEALTHCARE EXPENDITURES IN INFLAMMATORY BOWEL DISEASE

Burden of Gastrointestinal Symptoms in the United States: Results of a Nationally Representative Survey of Over 71,000 Americans

Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndrome

Burden of Bowel Urgency in Patients With Ulcerative Colitis and Crohn's Disease: A Real-World Global Study

Treatment for chronic idiopathic constipation: Use and satisfaction from a nationwide survey of US participants

THE COST OF INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED ANALYSIS OF ADMINISTRATIVE DATA

International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit

Observational Burden of Illness Study in Patients With Crohn's Disease With and Without Perianal Fistulas in the United States

An approach to the diagnosis and management of Rome IV functional disorders of chronic constipation

The cost of IBD care - how to make it sustainable

Natural History and Outcomes of Individuals with Functional Bowel Disorder: a 9-year Population-based Longitudinal Study

Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility